Vaxcyte exec surrenders 7,651 shares for tax

Vaxcyte’s Chief Technical Ops Officer surrendered shares to satisfy RSU tax withholding, with a direct holding of 68,085 shares remaining.

Available on EDGAR 09/09/2026 - 05:53 PM EDT Accepted by SEC EDGAR 09/09/2026 - 05:53 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reported that Chief Technical Ops Officer Harpreet S. Dhaliwal had 7,651 shares of common stock surrendered on September 8, 2026 to cover tax withholding obligations arising from vesting RSUs. The transaction was a share disposition for tax purposes, leaving 68,085 shares held directly after the event. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Tax Withholding: 7,651 shares

Tax Withholding 1 txn

Insider Dhaliwal Harpreet S.

Role Chief Technical Ops Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	7,651	$60.36	$462K

Holdings After Transaction: Common Stock — 68,085 shares (Direct)

Footnotes (1)

1. F1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Key Figures

Shares surrendered for tax withholding: 7,651 shares Reported price per share: $60.36 per share Shares held after transaction: 68,085 shares

3 metrics

Shares surrendered for tax withholding 7,651 shares Common stock surrendered on September 8, 2026 to cover RSU tax withholding

Reported price per share $60.36 per share Value used for the 7,651 surrendered shares

Shares held after transaction 68,085 shares Directly owned common stock following the September 8, 2026 disposition

Key Terms

Restricted Stock Units, tax withholding obligations, Rule 10b5-1

3 terms

Restricted Stock Units financial

"tax withholding obligations realized upon the vesting of RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"cover applicable tax withholding obligations realized upon the vesting"

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox is not checked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vaxcyte (PCVX) disclose for Harpreet S. Dhaliwal?

Vaxcyte disclosed that Chief Technical Ops Officer Harpreet S. Dhaliwal had 7,651 shares of common stock surrendered on September 8, 2026 to satisfy tax withholding obligations from vesting RSUs.

Was the Vaxcyte (PCVX) Form 4 transaction a market sale or tax withholding?

The Form 4 states the transaction was a payment of tax liability by delivering or withholding securities, meaning shares were surrendered for tax withholding, not reported as an open-market sale.

How many Vaxcyte (PCVX) shares does Harpreet S. Dhaliwal hold after this transaction?

After the September 8, 2026 tax-withholding disposition, Harpreet S. Dhaliwal is reported as directly holding 68,085 shares of Vaxcyte common stock.

At what value were the surrendered Vaxcyte (PCVX) shares reported?

The 7,651 surrendered shares were reported at $60.36 per share, consistent with the Form 4’s transaction price field treated on a per-share basis.

Was the Vaxcyte (PCVX) insider transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating a trading plan, so no Rule 10b5-1 plan is reported for this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dhaliwal Harpreet S.

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Ops Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		F		7,651(1)	D	$60.36	68,085	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Remarks:

	Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)